Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.37
(
0.83%
)
Bitcoin
76,900.90
(
-0.66%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 109598

Tuesday, 01/25/2011 4:15:49 PM

Tuesday, January 25, 2011 4:15:49 PM

Post# of 257580
GILD receives FDA Refusal-to-File letter for ‘Btripla’:

http://finance.yahoo.com/news/Gilead-Sciences-Receives-bw-2933689778.html?x=0&.v=1

Btripla is the combination pill consisting of GILD’s Truvada and JNJ’s TMC278. TMC278 is a qD NNRTI from JNJ that is similar to Intelence with better pharmacokinetics (#msg-57177651).

The RTF letter is clearly a surprising development.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today